FDA/EC/EMEA joint inspections
FDA has agreed to collaborate with the European Commission and European Medicines Agency on pilot projects involving joint inspections of pharmaceutical manufacturers in the U.S. and EU and of manufacturers of active pharmaceutical ingredients in "third" countries, the Transatlantic Economic Council announced at a May 13 meeting in Brussels. The organizations will also pilot the exchange of inspection results to better identify API manufacturers in third countries and will accelerate efforts to determine "to what extent dedicated production facilities are necessary for certain pharmaceuticals," according to a TEC summary. Formed in 2007, the TEC is designed to foster closer economic standards by harmonizing standards and is comprised of U.S. Cabinet members and European commissioners
You may also be interested in...
October seminar is planned in response to international requests; CDER will hold companion forum.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.